Clinical Trial Requirements for Veterinary Product Registration in South Africa

Registering a veterinary product in South Africa requires more than formulation data and manufacturing compliance. For most therapeutic, prophylactic, and certain pest control products, the Department of Agriculture, Land Reform and Rural Development (DALRRD, formerly DAFF) expects robust clinical trial evidence demonstrating that the product is safe for the target animal, effective for the claimed indication, and safe for the end consumer where food-producing species are involved. Getting the trial data package right is one of the most consequential steps in the registration process - and one of the most common sources of regulatory delays.

When Are Clinical Trials Required?

Not every veterinary product submission demands a full clinical trial programme. Stock remedies regulated under Act 36 of 1947 and certain lower-risk products may rely on published literature, bioequivalence data, or abbreviated safety assessments. However, clinical trials are typically mandatory in the following scenarios:

New chemical entities or novel fixed-dose combinations intended for therapeutic or prophylactic use require both target animal safety (TAS) studies and clinical efficacy trials. Products making new indication claims for an existing active substance must demonstrate efficacy for the specific claim, even if the compound itself is well characterised. Biologicals such as vaccines and immunological products require potency, safety, and field efficacy data, often under conditions specific to South African disease epidemiology. Where a product is intended for food-producing animals, residue depletion studies are also required to support withdrawal period claims, and these must comply with Maximum Residue Limit (MRL) frameworks.

Products falling under SAHPRA's jurisdiction - specifically Schedule 5 and above substances used in veterinary medicine - may trigger additional requirements aligned with SAHPRA's clinical trial guidelines, including formal Clinical Trial Committee (CTC) approval before study initiation.

Regulatory Framework and GCP Expectations

South Africa's expectations for veterinary clinical trials draw from two principal sources. DALRRD's Registrar of Act 36 evaluates stock remedy and agricultural remedy submissions, while SAHPRA oversees scheduled veterinary medicines under the Medicines and Related Substances Act (Act 101 of 1965). In practice, many applicants must navigate both authorities, and the evidentiary standards differ in emphasis though not in rigour.

The international benchmark is VICH GL9 - the guideline on Good Clinical Practice (GCP) for veterinary clinical trials, developed under the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. South African regulators expect compliance with VICH GCP principles, which govern study design, investigator responsibilities, data integrity, animal welfare, and reporting standards. Key requirements include a pre-approved study protocol with clearly defined endpoints, randomisation and appropriate controls (negative, positive, or placebo as scientifically justified), blinding where feasible to reduce assessment bias, documented informed owner consent for privately owned animals, and accurate, contemporaneous recording of all observations and adverse events.

Field trials conducted under South African conditions carry particular weight. Regulators are cautious about extrapolating efficacy data generated exclusively in temperate Northern Hemisphere environments to local breeds, management systems, parasite populations, and disease strains. Where foreign trial data forms the core of the submission, applicants should expect requests for bridging studies or at minimum a scientifically justified argument for extrapolation.

Common Deficiencies in Trial Data Submissions

Having reviewed hundreds of veterinary dossiers, certain patterns of deficiency recur with striking regularity. Protocol deviations are poorly documented or not documented at all, leaving reviewers unable to assess whether the deviation compromised data integrity. Statistical analysis plans are either absent from the protocol or changed post hoc without justification - a red flag for any regulator.

Inadequate sample sizes undermine statistical power and render efficacy conclusions unconvincing. This is especially common in large animal studies where practical and economic constraints tempt sponsors to cut numbers below what the study design demands. Adverse event reporting is another weak point: mild or transient reactions in target animals are frequently omitted from the clinical report, creating an incomplete safety profile.

For food-producing species, residue studies sometimes fail to include the correct target tissues or use analytical methods that have not been validated to the required limit of quantification. Withdrawal period calculations based on insufficient data points or inappropriate statistical methods (using arithmetic means rather than the required tolerance limit approach, for instance) are a frequent cause of queries.

Finally, many submissions lack a coherent integrated summary that synthesises findings across studies into a cohesive benefit-risk narrative. Regulators do not simply want raw data - they want the applicant's own critical evaluation of what that data means.

How Avidara Supports Trial Documentation Review

Getting clinical trial documentation right before submission is far more efficient than responding to rounds of regulatory queries after the fact. Avidara's Dossier Review service provides a pre-submission assessment of your veterinary clinical data package, evaluating protocol compliance, statistical integrity, GCP adherence, and alignment with DALRRD and SAHPRA expectations. Our reviewers flag the specific deficiencies that trigger queries - so you can address them before the regulator sees the file. If your trial data package needs a critical eye before it reaches the Registrar's desk, book a review.